Global Epigenetic Antibodies Market Overview
The Epigenetic Antibodies Market Size was valued at USD 1.9 Billion in 2023. The Epigenetic Antibodies Market industry is projected to grow from USD 2.2 Billion in 2024 to USD 7.14 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 18.00% during the forecast period (2024 - 2032). The rising investment in R&D, declining sequencing cost & time, favorable government initiatives & funding for epigenetics research, and advancement in technology for epigenetic research are expected to be significant market drivers for the Epigenetic Antibodies Market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Epigenetic Antibodies Market Trends
- The rising prevalence of cancer and the rise in the aging population are driving market growth.
Market CAGR for Epigenetic Antibodies is driven by the rising prevalence of cancer and the rise in the aging population. The recorded 1,603,844 new cancer cases and 602,347 cancer-related deaths year alone in the United States in 2020 indicate the gravity of the situation. This, therefore, means that the number of people who develop cancer out of 100,000 persons is at least 144, and 403 deaths occur. Indeed, in 2025, as per the ICMR-NCRP projection, there will be almost 16 lakh cancer cases in India, while the other figure is 14.6 lakh cancer cases in India for 2022. Not less important, several research institutions are getting the 'deep' of epigenetics because of its profound effect, which enables the development of effective vaccines for cancers.
The World Health Organization, in its WHO World Report on Aging and Health (2020), predicts that ly, the population of individuals 65 years and above is likely to double by 2050 from its 2019 figure of 1 billion, with most of the increase coming from developing countries, the world is faced with a growing aging population. This age group is the fastest-growing group in the country, with the number of Americans in this age bracket expected to explode by 47% (from 58 million in 2022 to 82 million in 2050). Additionally, the population of US citizens over the age of 65 is anticipated to increase by 15% to 23% by 2030. Researchers suggest that immunity to certain diseases is reduced concerning aging, and this predisposition for neurological and cardiovascular conditions also comes with the natural aging process. Also, with age, the immune system is weakened, and the possibility of catching any bacterial or viral infections is enhanced.
As a result, it is anticipated that throughout the projection period, demand for the Epigenetic Antibodies Market will increase due to the rising prevalence of cancer and the rise in the aging population. Thus, driving the Epigenetic Antibodies Market revenue.
Epigenetic Antibodies Market Segment Insights
Epigenetic Antibodies Market Product & Service Insights
The Epigenetic Antibodies Market segmentation, based on Product & Service, includes Kits & Reagents, Enzymes, Instruments and Accessories, Software, and Service. The Kits & Reagents segment dominated the market, accounting for 58% of market revenue. A variety of techniques, including DNA methylation, chromatin analysis, histone analysis, and sequencing, are used in the study of epigenetics using kits and reagents. Depending on the analytical method, kits are ready-to-use assays that include primers, controls, columns, buffers, beads, inhibitors, and antibodies. Reagents can be used in varying concentrations based on the needs of the operation or analysis; they are sold separately.
Epigenetic Antibodies Market Method Insights
The Epigenetic Antibodies Market segmentation, based on Method, includes DNA Methylation, Histone Modifications, and Other Methods (non-coding RNA and chromatin remodeling). The DNA Methylation segment dominated the market, accounting for 58% of market revenue. The rising incidence of cancer and technological developments in PCR, sequencing, and chip-based detection, which allow for the quick execution and affordable sequencing of targeted regions of interest, are both responsible for the segment's significant share. Additionally, the segment's large share is supported by the growing emphasis on cutting costs related to lengthy research and product approval processes.
Figure 1: Epigenetic Antibodies Market, by Method, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Epigenetic Antibodies Market Technique Insights
The Epigenetic Antibodies Market segmentation, based on Technique, includes NGS, PCR & qPCR, Mass Spectrometry, Sonication, and Other Techniques (magnetic separators and microarrays). The Mass Spectrometry segment dominated the market, accounting for 60% of market revenue. Mass spectrometry enables a thorough examination of epigenetic changes throughout the genome, allowing researchers to detect multiple marks simultaneously. This is a significant improvement over traditional antibody-based methods, which may be limited in terms of specificity and scope. As a result, scientists have gained a deeper insight into epigenetic regulation and its impact on various biological processes and disorders.
Epigenetic Antibodies Market Application Insights
The Epigenetic Antibodies Market segmentation, based on Application, includes Oncology, Metabolic Diseases, Immunology, Developmental Biology, Cardiovascular Diseases, and Other Applications (neurology, infectious diseases, and gynecology). The Oncology segment dominated the market, accounting for 60% of market revenue. The number of cancer cases is increasing, thanks to government efforts to raise awareness and progress in research. The International Agency for Research on Cancer predicts a significant rise in new cases by 2030, reaching 24.5 million compared to 19.2 million in 2020. Sadly, the number of cancer-related deaths is also expected to climb from 9.9 million in 2020 to 12.9 million in 2030. Researchers are exploring ways to personalize cancer treatment by targeting epigenetic changes in cancer cells to make them more responsive to anti-cancer drugs like chemotherapy.
Epigenetic Antibodies Market End User Insights
The Epigenetic Antibodies Market segmentation, based on End User, includes Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, and Hospitals & Clinics. The Pharmaceutical & Biotechnology Companies segment dominated the market, accounting for 60% of market revenue. The increase in chronic diseases, higher research and development spending by pharmaceutical and biotechnology companies, the launch of new epigenetics products for rare and chronic diseases, and advancements in epigenetics technology all contribute to the significant market share of this sector. Pharmaceutical and biotechnology firms can leverage epigenetics to validate and discover disease mechanisms and interactions that can help in the development of innovative diagnostic tests and treatments. Epigenetic markers are measurable signals of a biological state or process that can identify genetic variations, alterations in gene expression, or epigenetic changes associated with a particular disease or condition, as well as aid in diagnosis.
Epigenetic Antibodies Market Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The anticipated expansion of the Epigenetic Antibodies market in North America can be attributed to several key factors. The healthcare sector in North America is growing rapidly, driven by a high prevalence of chronic diseases, substantial investments in research and development, and a sophisticated healthcare system. In 2022, the United States spent $4.5 trillion on healthcare, with an average of $13,493 per person, accounting for 17.3% of the country's GDP. The US had the highest health expenditure to GDP ratio at 16.6%, followed by Germany at 12.7% and France at 12.1%. The biotechnology and pharmaceutical industries in the region are making significant advancements in research and technology related to epigenetics, contributing to the growth of the market.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 2: Epigenetic Antibodies Market Share By Region 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Epigenetic Antibodies Market accounts for the second-largest market share as significant investments are being made in healthcare research and development, and Europe boasts a strong healthcare infrastructure. In 2020, the EU Member States with the highest healthcare expenditures in GDP were Germany (12.8%) and France (12.2%). The overall current healthcare expenditure in Czechia (where the highest share was reported, at 87.7%), Luxembourg, Sweden, and Germany was above 85.0% when the combined share of government schemes and mandatory schemes/accounts was taken into consideration. It was also above 85.0% in Norway. Supporting research studies, product development, and funding initiatives from governmental authorities, private organizations, and pharmaceutical companies are driving the market expansion for epigenetic antibodies. Further, the German Epigenetic Antibodies Market held the largest market share, and the UK Epigenetic Antibodies Market was the fastest-growing market in the European region.
The Asia-Pacific Epigenetic Antibodies Market is expected to grow at the fastest CAGR from 2024 to 2032. Due to the region's diverse population and high incidence of several cancers, the market has the potential to grow. Moreover, initiatives to advance personalized medicine and infrastructure advancements in the healthcare sector are credited with driving the epigenetic market's growth in the Asia Pacific region. With an average prevalence of 100.4 cases per 100,000 people, 1,461,427 new cases of cancer will be identified in India in 2022. In India, one in nine people are predicted to receive a cancer diagnosis at some point in their lives. According to projections, India's cancer burden will increase from 26.7 million DALYs (adjusted mortality to incidence) in 2021 to 29.8 million in 2025, with the north and northeast experiencing the greatest burden. Cardiovascular disease is the non-communicable disease that most significantly contributes to the death rate (63.3%), followed by cancer (18.1%). The Ministry of Health and Family Welfare (MoHFW) received Rs. 89,155 crore (US$ 10.76 billion) from the government in the Union Budget 2023–24. Moreover, China’s Epigenetic Antibodies Market held the largest market share, and the Indian Epigenetic Antibodies Market was the fastest-growing market in the Asia-Pacific region.
Epigenetic Antibodies Market Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the Epigenetic Antibodies market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Epigenetic Antibodies industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Epigenetic Antibodies industry to benefit clients and increase the market sector. In recent years, the Epigenetic Antibodies industry has offered some of the most significant advantages to various sectors and applications, ranging from manufacturing and construction to agriculture and transportation. Major players in the Epigenetic Antibodies Market, including Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Merck KGaA (Germany), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US), Qiagen (Germany) are attempting to increase market demand by investing in research and development operations.
In the fields of molecular diagnostics, consumer and translational genomics, and cancer, Illumina Inc. (Illumina) provides array-based genetic analysis solutions and genomic sequencing. The products offered by the company include arrays and reagents, molecular biology reagents, microarray kits and reagents, sequencing tools and systems, and sequencing kits and reagents. It provides training, consultation, instrument services, microarray services, and human whole-genome sequencing. The business's clientele includes biotechnology firms, academic institutions, pharmaceutical companies, genomic research centers, and clinical research organizations. Direct sales and distributors across the Americas, Asia-Pacific, Europe, the Middle East, and Africa are how the company sells its products. The US city of San Diego, California, is home to Illumina's headquarters. Illumina, Inc. (US) and SomaLogic (US) signed an agreement in January 2022 for the introduction of the SomaScan Proteomics Assay into high throughput next-generation sequencing (NGS) platforms manufactured by Illumina.
Analytical instruments, life sciences solutions, specialized diagnostics, laboratory, pharmaceutical, and biotechnology services are all offered by Thermo Fisher Scientific Inc. (Thermo Fisher). The company provides a wide range of products, such as chemicals, cell culture materials, tools for protein and cell analysis, laboratory supplies, equipment, instruments, clinical and diagnostic tools, chromatography and mass spectrometry devices, and products for molecular biology and nucleic acid analysis. Applications for Thermo Fisher's products and services can be found in several industries, including biotechnology, forensics, pharmaceuticals, food and beverage, and industrial and applied sciences. The company uses supply-chain management services for distribution, e-commerce capabilities, industry-specific catalogs, and direct sales representatives to run its operations. The US town of Waltham, Massachusetts, is home to Thermo Fisher's headquarters.
Key companies in the Epigenetic Antibodies Market include.
Epigenetic Antibodies Industry Developments
August 2023: PacBio (US) acquired Apton Biosystems (US) to expedite the development of a next-generation, high-throughput, short-read sequencer.
March 2022: Thermofisher Scientific Inc. (US) launched the CE IVD Marked Next Generation Sequencing Instrument. This instrument has been designed to be used in clinical laboratories to perform clinical research and diagnostic testing on a single instrument.
Epigenetic Antibodies Market Segmentation
Epigenetic Antibodies Market Product & Service Outlook
- Kits & Reagents
- Enzymes
- Instruments and Accessories
- Software
- Service
Epigenetic Antibodies Market Method Outlook
- DNA Methylation
- Histone Modifications
- Other Methods (non-coding RNA and chromatin remodeling)
Epigenetic Antibodies Market Technique Outlook
- NGS
- PCR & qPCR
- Mass Spectrometry
- Sonication
- Other Techniques (magnetic separators and microarrays)
Epigenetic Antibodies Market Application Outlook
- Oncology
- Metabolic Diseases
- Immunology
- Developmental Biology
- Cardiovascular Diseases
- Other Applications (neurology, infectious diseases, and gynecology)
Epigenetic Antibodies Market End User Outlook
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Hospitals & Clinics
Epigenetic Antibodies Market Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
Epigenetic Antibodies Market Report Scope
| Report Attribute/Metric |
Details |
| Market Size 2023 |
USD 1.9 Billion |
| Market Size 2024 |
USD 2.2 Billion |
| Market Size 2032 |
USD 7.14 Billion |
| Compound Annual Growth Rate (CAGR) |
18.00% (2024-2032) |
| Base Year |
2023 |
| Market Forecast Period |
2024-2032 |
| Historical Data |
2019- 2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Product & Service, Method, Technique, Application, End User, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea |
| Key Companies Profiled |
Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Merck KGaA (Germany), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US), Qiagen (Germany) |
| Key Market Opportunities |
Integration of artificial intelligence and machine learning algorithms |
| Key Market Dynamics |
Growing investments in research & development |
Frequently Asked Questions (FAQ) :
The Epigenetic Antibodies Market size was valued at USD 1.9 Billion in 2023.
The Epigenetic Antibodies Market is projected to grow at a CAGR of 18.00% during the forecast period 2024-2032.
North America had the largest share of the global market.
The key players in the market are Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Merck KGaA (Germany), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US), Qiagen (Germany), and others.
The Kits & Reagents segment dominated the market in 2023.
The Oncology segment had the largest share in the global market.
